@xconomy.com 6 days ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 1 month ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 6 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 6 months ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 7 months ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 9 months ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 9 months ago
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund
@xconomy.com 10 months ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 10 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 11 months ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 11 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@techcrunch.com 1 year ago
Only 2% of genomic material available for research comes from Africa, 54gene wants to change that
@xconomy.com 1 year ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 1 year ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@techcrunch.com 1 year ago
Healthcare by 2028 will be doctor-directed, patient-owned and powered by visual technologies
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 1 year ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com 1 year ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 1 year ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 1 year ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com 2 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 2 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More